-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4206 Association of Latino Ethnicity with Cytogenetic Subtype in Pediatric Acute Lymphoblastic Leukemia: A Report from the Reducing Ethnic Disparities in Acute Leukemia Consortium

Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, ALL, Diseases, Lymphoid Malignancies
Monday, December 11, 2023, 6:00 PM-8:00 PM

Maria D. Leon-Camarena, MD1, Jennifer M. Geris, PhD, MPH2*, Maria Isabel Castellanos, MD3*, Olga Taylor4*, Veronica Garcia-Morales2*, Austin L Brown, PhD4*, Pagna Sok4*, Van Thu Huynh5, Kathleen Ludwig, MD6*, Laura J. Klesse, MD, PhD6*, Sandi Pruitt, PhD, MPH7*, Amy Hughes, PhD7*, Kevin Wells Tien, MD2, Kenneth Matthew Heym, MD8*, Timothy Griffin, MD9*, Rodrigo Erana, MD2*, Juan C. Bernini, MD2*, Philip J. Lupo, PhD10*, M. Monica Gramatges, MD, PhD11, Michael E. Scheurer, PhD2 and Karen R. Rabin, MD, PhD12

1Internal Medicine, Dell Medical School at University of Texas, Austin, TX
2Department of Pediatrics, Baylor College of Medicine, Houston, TX
3University of California San Francisco, San Francisco, CA
4Baylor College of Medicine, Houston, TX
5Children’s Hospitals of Orange County, Orange, CA
6University of Texas Southwestern, Dallas, TX
7Peter O’ Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX
8Department of Pediatrics, Cook Children's Medical Center, Fort Worth, TX
9Department of Hematology-Oncology, The Children’s Hospital of San Antonio/Baylor College of Medicine, San Antonio, TX
10Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
11Pediatric Hematology-Oncology, Texas Children's Hospital, Houston, TX
12Department of Pediatrics, Baylor College of Medicine, Baylor College of Medicine TX Children's Cancer Center, Houston, TX

Introduction: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and is a heterogeneous group of bone marrow diseases with multiple cytogenetic subtypes leading to distinct clinical outcomes. Despite advances in treatments that improve survival, racial and ethnic disparities continue to persist. Latino children have a higher incidence of ALL and poorer overall survival compared with non-Latino white children. Although several studies conducted have identified cytogenetic differences in Latinos, larger studies are needed to confirm and further elaborate these findings. The aim of our study was to analyze cytogenic profiles of a large, diverse cohort of children with ALL to assess the associate between cytogenic subtypes in Latino ethnicity.

Methods: We analyzed the distribution of ALL subtypes and self-reported race/ethnicity in the Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium retrospective registry, which includes patients (age 0-24 at diagnosed) with newly diagnosed ALL from six pediatric cancer centers in the southwest region that were diagnosed between 2017 – 2021. The demographic and clinical factors included self-reported race/ethnicity, sex, age at diagnosis, immunophenotype, and cytogenetic aberration. Cytogenetic subtypes evaluated included double trisomies (DT; trisomies chromosomes 4 and 10), BCR::ABL (Ph+), ETV6::RUNX1, KMT2A (MLL) rearrangements, hypodiploidy, intrachromosomal amplification of chromosome 21 (iAMP21), TCF3::PBX1, IGH, and CRLF2 rearrangements. Multivariable logistic regression models were used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs), accounting for sex and age at diagnosis.

Results: Of the 2,388 ALL patients evaluated, 90.2% had B-cell ALL and 64.4% self-identified as Latino and the mean age at diagnosis was 6.6 years. Compared with non-Latino white patients, the cytogenetic findings associated with favorable prognosis, DT and ETV6::RUNX1 t(12;21), were less frequent in Latino patients (aOR: 0.80, 95% CI: 0.65-0.98 for DT and aOR: 0.67, 95% CI: 0.53-0.85 for ETV6::RUNX1). Overall, favorable cytogenetics were less frequent among Latino children compared with non-Latino white children (aOR: 0.82, 95% CI: 0.67-0.99). The neutral cytogenetic subtype TCF3::PBX1 was also less frequent clinically among Latino patients (aOR: 0.39, 95% CI: 0.18 - 0.85). Among unfavorable cytogenetic alterations, iAMP21 was significantly less frequent among Latino children compared with non-Latino white children (aOR: 0.57, 95% CI: 0.32-0.99). There was no significant association between other unfavorable cytogenetic subtypes and Latino ethnicity, either individually or for the overall unfavorable group.

Conclusions: Overall, our findings indicate that Latino children are significantly less likely to have favorable cytogenetic subtypes, TCF3::PBX1 and iAMP21 and prognostically neutral cytogenetics. Further evaluation of cytogenetic subtypes and race/ethnicity may elucidate their contribution to outcome disparities.

Disclosures: Huynh: Servier: Research Funding.

*signifies non-member of ASH